Pediatric neurology · 2026
Patterns of Response to Treatment and Outcome of Childhood Absence Epilepsy: A Multicenter Study From Saudi Arabia.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alharthi Raghad Shiraz, Alrifai Muhammad Talal, Alomari Raghad Darwish, Alghurayer Raghad Yousef, Alkewaibeen Abdulaziz, Altuwaijri Waleed, Alrumayyan Ahmed, Aldrees Amjad, Almuqbil Mohammed
Аннотация
BACKGROUND: Childhood absence epilepsy (CAE) is a common pediatric epilepsy syndrome affecting school-aged children. While generally considered benign, recent studies indicate that a significant proportion of patients experience pharmaco-resistance and neuropsychiatric comorbidities. This study aimed to investigate the outcomes of CAE patients across tertiary care centers in Saudi Arabia.
METHODS: A retrospective cohort study was conducted at multiple tertiary care centers in Saudi Arabia. The study included 61 pediatric patients (≤14 years) with confirmed CAE diagnosis. Data were collected from electronic medical records. Response to treatment was defined as >50% reduction in seizure frequency from the baseline, while terminal remission was defined as one-year seizure-free off antiseizure medications.
RESULTS: The study population had an equal gender distribution (50.8% male) with a median age of 7 years at diagnosis. Most patients (93.4%) had no comorbidities. The majority (88.5%) achieved response to appropriate antiseizure medications; of these responders, 27.8% achieved terminal remission, while 11.5% demonstrated no response. Isolated staring episodes were the predominant presentation (88.5%). Most patients (93.4%) were managed with monotherapy, with valproic acid (60.7%) being the most commonly prescribed medication, followed by ethosuximide (36.1%). Age at diagnosis showed a positive association with recurrence risk, though not statistically significant.
CONCLUSIONS: CAE patients in Saudi Arabian tertiary care centers demonstrate favorable outcomes, with high response rates with monotherapy. Early diagnosis and treatment may improve prognosis, as suggested by the trend toward higher recurrence rates in patients diagnosed at older ages.
METHODS: A retrospective cohort study was conducted at multiple tertiary care centers in Saudi Arabia. The study included 61 pediatric patients (≤14 years) with confirmed CAE diagnosis. Data were collected from electronic medical records. Response to treatment was defined as >50% reduction in seizure frequency from the baseline, while terminal remission was defined as one-year seizure-free off antiseizure medications.
RESULTS: The study population had an equal gender distribution (50.8% male) with a median age of 7 years at diagnosis. Most patients (93.4%) had no comorbidities. The majority (88.5%) achieved response to appropriate antiseizure medications; of these responders, 27.8% achieved terminal remission, while 11.5% demonstrated no response. Isolated staring episodes were the predominant presentation (88.5%). Most patients (93.4%) were managed with monotherapy, with valproic acid (60.7%) being the most commonly prescribed medication, followed by ethosuximide (36.1%). Age at diagnosis showed a positive association with recurrence risk, though not statistically significant.
CONCLUSIONS: CAE patients in Saudi Arabian tertiary care centers demonstrate favorable outcomes, with high response rates with monotherapy. Early diagnosis and treatment may improve prognosis, as suggested by the trend toward higher recurrence rates in patients diagnosed at older ages.